期刊文献+

疼痛中枢敏化的新机制——肠促胰岛素信号的作用 被引量:6

A new mechanism of central sensitization underlying pain--the role of incretin hormones signaling
原文传递
导出
摘要 背景脊髓中枢敏化是引起疼痛的主要机制之一,以往对肠促胰岛素的研究局限于胰岛素相关作用,最新的研究发现肠促胰岛索可能参与了疼痛中枢敏化过程。目的回顾近年来国内外关于肠促胰岛素参与疼痛中枢敏化的研究。内容肠促胰岛素的生理特点和受体表达分布,胰高血糖素样肽-1(glucagon like peptide-1,GLP-1)及其受体和葡萄糖依赖性促胰岛素分泌多肽(glucosel-dependent insulinotropic polypeptide,GIP)及其受体参与中枢可塑性和痛觉中枢敏化的机制,GLP-1和GIP信号系统“交叉对话”参与中枢敏化的潜在机制。趋向肠促胰岛素信号系统及其“交叉谈话”机制是疼痛中枢敏化的重要新机制。 Background Central sensitization is a main mechanism underlying pain. Incretin is confined to mediate insulinmimetic effects, but recent study indicates that incretin may affect the central sensitization of pain. Objective This article reviews the studies about the effects of incretin on central sensitization of spinal cord in pain. Content This review summarized physiological characters and receptor localization of incretin. Glueagon like peptide-1 (GLP-1) and its receptor, glucose-dependent insulinotropic polypeptide (GIP) and its receptor influence the neuronal plasticity and the central sensitization of pain. The cross-talk between GLP-1 and GIP signaling pathway is a potential mechanism of the central sensitization underlying pain. Trend Central sensitization underlying pain can be induced by incretin signaling system and their cross-talk is an important and novel concept.
作者 孙雨晴 王云 Sun Yuqing;Wang Yun(Department of Anesthesiology,Beijing Chaoyang Hospital,Capital Medical University,Beijing 100020,China(Sun YQ,Wang Y)
出处 《国际麻醉学与复苏杂志》 CAS 2018年第9期892-895,904,共5页 International Journal of Anesthesiology and Resuscitation
基金 国家自然科学基金(81400909,81571065) 北京市自然科学基金(7152056)
关键词 葡萄糖依赖性促胰岛素分泌多肽 胰高血糖素样肽-1 疼痛 神经可塑性 Glucose-dependent insulinotropic polypeptide Glucagon like peptide-1 Pain Neural plasticity
  • 相关文献

参考文献2

二级参考文献35

  • 1杨立业,黄天华.GLP-1(1~37)诱导人类胚胎小肠上皮细胞表达胰岛素[J].生物化学与生物物理进展,2005,32(6):576-580. 被引量:2
  • 2王璐,邸阜生.肠促胰岛素类似物和DPP-Ⅳ抑制剂在2型糖尿病治疗中的作用[J].医学综述,2007,13(1):25-27. 被引量:6
  • 3高虹,宁光.胰高血糖素样肽1的胰腺外作用研究进展[J].国际内科学杂志,2007,34(7):408-411. 被引量:25
  • 4Pratley RE,Matfin G.Pre-diabetes:clinical relevance and therapeutic approach[J].Diabetes Vasc Dis,2007,7(6):120-129.
  • 5Nauck M.Glucgon-like peptide-1 in type 2 diabetes:the B cell and beyond[J].Diabetes Obes Metab,2008,10(2):2-13.
  • 6Unger RH,Eisentraut AM.Entero-insular axis[J].Archs Intern Med,1969,123(3):261-266.
  • 7Hoist JJ.The physiology of glucagon-like peptide-1[J].Physiol Rev,2007,87(4):1409-1439.
  • 8Suzuki A,Nakauchi H,Taniguchi H.Glucagon-like peptide 1(1-37) converts intestinal epithelial cells into insulinproducing cells[J].Proc Nat Acad Sci,2003,100(4):5034-5039.
  • 9Meier JJ,Gallwitz B,Wolfgang E,et al.Glucagon-like peptide 1 as a regulator of food intake and body weight:therapeutic perspectives[J].Eur J Pharmacol,2002,440(8):269-279.
  • 10Kendall DM,Riddle MC,Rosenstock J,et al.Effects of exenatide(exendin-4) on glycemic control over 30 weeks in patients with type 2 diabetes treated with metformin and a sulfonylurea[J].Diabetes Care,2005,28(5):1083-1091.

共引文献18

同被引文献43

引证文献6

二级引证文献15

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部